|
Open Orphan PLC - London-based pharmaceutical services - Says Thursday that results from the world's first Covid-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. Says study showed the SARS-CoV-2 human challenge was safe in healthy young adults and provided insights into the course of Covid-19 infection with potential positive public health implications. With the characterisation study disease modelling data completed, and human challenge model established, Open Orphan says it should be able to conduct Covid-19 human challenge studies in 2022.
Chief Executive Officer Yamin Khan says: ‘I am pleased to see the characterisation study paper successfully complete the peer review process and be published in such a prestigious journal. Looking forward to the rest of the year, the COVID-19 human challenge model has the potential to accelerate the development of novel therapeutics and vaccines. We look forward to updating the market in due course.’
Current stock price: 14.25 pence
12-month change: down 58%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
